Comparison of Human Placenta- and Bone Marrow–Derived Multipotent Mesenchymal Stem Cells
- 1 December 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 17 (6), 1095-1108
- https://doi.org/10.1089/scd.2007.0154
Abstract
Bone marrow is the traditional source of human multipotent mesenchymal stem cells (MSCs), but placenta appears to be an alternative and more readily available source. This study comprehensively compared human placenta–derived MSC (hpMSC) and human bone marrow–derived MSC (hbmMSC) in terms of cell characteristics, optimal growth conditions and in vivo safety specifically to determine if hpMSC could represent a source of human MSC for clinical trial. MSC were isolated from human placenta (hpMSC) and human bone marrow (hbmMSC) and expanded ex vivo using good manufacturing practice–compliant reagents. hpMSC and hbmMSC showed similar proliferation characteristics in different basal culture media types, fetal calf serum (FCS) concentrations, FCS heat-inactivation experiments, flask types and media replacement responsiveness. However, hpMSC and hbmMSC differed with respect to their proliferation capabilities at different seeding densities, with hbmMSC proliferating more slowly than hpMSC in every experiment. hpMSC had greater long-term growth ability than hbmMSC. MSC from both sources exhibited similar light microscopy morphology, size, cell surface phenotype, and mesodermal differentiation ability with the exception that hpMSC consistently appeared less able to differentiate to the adipogenic lineage. A comparison of both hbmMSC and hpMSC from early and medium passage cultures using single-nucleotide polymorphism (SNP) GeneChip analysis confirmed GTG-banding data that no copy number changes had been acquired during sequential passaging. In three of three informative cases (in which the gender of the delivered baby was male), hpMSC were of maternal origin. Neither hpMSC nor hbmMSC caused any acute toxicity in normal mice when injected intravenously at the same, or higher, doses than those currently used in clinical trials of hbmMSC. This study suggests that human placenta is an acceptable alternative source for human MSC and their use is currently being evaluated in clinical trials.Keywords
This publication has 36 references indexed in Scilit:
- Systemic Infusion of FLK1+ Mesenchymal Stem Cells Ameliorate Carbon Tetrachloride-Induced Liver Fibrosis in MiceTransplantation, 2004
- Isolation of multipotent mesenchymal stem cells from umbilical cord bloodBlood, 2004
- Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potentialBlood, 2004
- Lack of the CD8+ cell anti-HIV factor in CD8+ cell granulesBlood, 2003
- Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesisJournal of Neuroscience Research, 2002
- Mesenchymal stem cells promote engraftment of human umbilical cord blood–derived CD34+ cells in NOD/SCID miceExperimental Hematology, 2002
- Pluripotency of mesenchymal stem cells derived from adult marrowNature, 2002
- Human Bone Marrow Stem Cells Exhibit Neural Phenotypes and Ameliorate Neurological Deficits after Grafting into the Ischemic Brain of RatsExperimental Neurology, 2002
- Mobilized bone marrow cells repair the infarcted heart, improving function and survivalProceedings of the National Academy of Sciences of the United States of America, 2001
- Multilineage Potential of Adult Human Mesenchymal Stem CellsScience, 1999